BMC infectious diseases · 2026
Multi-year population-based study of the clinical and epidemiological risk factors for mortality in nocardiosis: survival analysis from a large regional Canadian healthcare region.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Church Deirdre, Ugarte-Torres Alejandra, Naugler Christopher
Аннотация
BACKGROUND: Nocardiae are ubiquitous environmental soil pathogens that primarily cause invasive infections by inhalation or direct skin inoculation in immunocompromised patients. This multi-year population-based study compared epidemiological and clinical features of all cases diagnosed in our region.
METHODS: Patients were enrolled in our large integrated healthcare region with culture-proven nocardiosis between 2010 and 2021. Clinical chart reviews were conducted to determine the clinical manifestations, risk factors, treatment and mortality including survival analysis.
RESULTS: Ninety-four adults had a mean age of 61 ± 17 years. More cases occurred in males (57%) than females (43%). 96% of cases had underlying co-morbidities including diabetes, liver or renal failure, malignancy, transplant recipients, chronic lung disease, rheumatologic disease, or other inflammatory conditions. Pulmonary (53%) or skin and soft tissue infections (SSTIs) (30%) commonly occurred with infrequent diagnoses of central nervous system infection (CNS) (7%), bloodstream infection (BSI) (6%), and septic arthritis or intra-abdominal infection (IAI) (6%). Diverse Nocardia spp. were isolated, but 3 species complexes caused most cases [56/94 (60%)] including Nocardia farcinica (n = 21, 22.3%), Nocardia cyriacigeorgica (n = 16, 17%) and Nocardia nova (n = 19, 20.2%). Clinical presentation was not unique for individual Nocardia spp.
INFECTIONS: Overall mortality was 17.6% with a 1-year mortality of 13.2%. Delayed diagnosis (≥ 30 d) from symptom onset had higher mortality. A trend towards increased mortality occurred for N. farcinica > N. cyriacigeorgica > N. nova complex infections.
CONCLUSIONS: Prompt diagnosis of nocardiosis improves patient outcomes. Nocardia species-level identification predicts mortality for major species complexes causing nocardiosis in our region.
CLINICA TRIAL NUMBER: Not applicable.
METHODS: Patients were enrolled in our large integrated healthcare region with culture-proven nocardiosis between 2010 and 2021. Clinical chart reviews were conducted to determine the clinical manifestations, risk factors, treatment and mortality including survival analysis.
RESULTS: Ninety-four adults had a mean age of 61 ± 17 years. More cases occurred in males (57%) than females (43%). 96% of cases had underlying co-morbidities including diabetes, liver or renal failure, malignancy, transplant recipients, chronic lung disease, rheumatologic disease, or other inflammatory conditions. Pulmonary (53%) or skin and soft tissue infections (SSTIs) (30%) commonly occurred with infrequent diagnoses of central nervous system infection (CNS) (7%), bloodstream infection (BSI) (6%), and septic arthritis or intra-abdominal infection (IAI) (6%). Diverse Nocardia spp. were isolated, but 3 species complexes caused most cases [56/94 (60%)] including Nocardia farcinica (n = 21, 22.3%), Nocardia cyriacigeorgica (n = 16, 17%) and Nocardia nova (n = 19, 20.2%). Clinical presentation was not unique for individual Nocardia spp.
INFECTIONS: Overall mortality was 17.6% with a 1-year mortality of 13.2%. Delayed diagnosis (≥ 30 d) from symptom onset had higher mortality. A trend towards increased mortality occurred for N. farcinica > N. cyriacigeorgica > N. nova complex infections.
CONCLUSIONS: Prompt diagnosis of nocardiosis improves patient outcomes. Nocardia species-level identification predicts mortality for major species complexes causing nocardiosis in our region.
CLINICA TRIAL NUMBER: Not applicable.